A Sedation/Cognition/EEG Study using AZD6280 and Comparator

Study identifier:D0850C00014

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A phase 1, single centre, single dose, double-blind, double-dummy, four-way crossover, placebo-controlled, randomized study to investigate the effects of AZD6280 on sedation, cognition and EEG in comparison with lorazepam in healthy male volunteers

Medical condition

Healthy Volunteer

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD6280, Lorazepam, Placebo

Sex

Male

Actual Enrollment

17

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Sept 2008
Primary Completion Date: -
Study Completion Date: 01 Dec 2008

Study design

Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria